Effect of phosphorothioate modifications on the ability of GTn oligodeoxynucleotides to specifically recognize single-stranded DNA-binding proteins and to affect human cancer cellular growth

Biochimie

Volumn 81, Issue 12, 1999, Pages 1115-1122

  Morassutti, Carla ^a   Scaggiante, Bruna ^a   Dapas, Barbara ^a   Xodo, Luigi ^a   Tell, Gianluca ^a   Quadrifoglio, Franco ^a  

^a UNIVERSITY OF UDINE   (Italy)

Author keywords

Cytotoxicity; Human T lymphoblasts; Nuclear proteins; Phosphorothioate oligonucleotides

Indexed keywords

DNA BINDING PROTEIN; OLIGODEOXYNUCLEOTIDE; PHOSPHOROTHIOIC ACID DERIVATIVE;

ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG PROTEIN BINDING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LEUKEMIA CELL;

EID: 0033428608     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(99)00350-8     Document Type: Article

References (31)

1. Cohen J.S. Towards a new chemiotherapy: oligodeoxynucleotide analogues as informational drugs. Huber B.E. Cancer Therapy in the Twenty-First Century, vol I., Molecular & Immunological Approaches. 1994;145-162 Futura Publ. Co. Inc., Mount Kisco.
2. Temsamani J., Tang J.Y., Padmapriya A., Kubert M., Agrawal S. Pharmacokinetics, biodistribution and stability of capped oligodeoxynucleotide phosphorothioates in mice. Antisense Res. Dev. 3:1993;277-284.
3. Zamecnik P., Aghajanian J., Zamecnik M., Goodchild J., Witman G. Electron micrographic studies of transport of oligodeoxynucleotides across eukaryotic cell membranes. Proc. Natl. Acad. Sci. USA. 91:1994;3156-3160.
4. Wagner R.W. Gene inhibition using antisense oligodeoxynucleotides. Nature. 372:1994;333-335.
5. Akhtar S., Agrawal S. In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18:1997;12-18.
6. Scaggiante B., Morassutti C., Tolazzi G., Michelutti A., Baccarani M., Quadrifoglio F. Effect of unmodified triple helix-forming oligodeoxyribonucleotide targeted to human multidrug-resistance gene mdr1 in MDR cancer cells. FEBS Lett. 352:1994;380-384.
7. Alunni-Fabbroni M., Pirulli D., Manzini G., Xodo L. AG oligonucleotides form extraordinary stable triple helices with a critical RY sequence of the murine Ki-ras promoter and inhibit transcription in transfected NIH 3T3 cells. Biochemistry. 35:1996;16361-16369.
8. Aharoni A., Baran N., Manor H. Characterization of a multisubunit human protein which selectively binds single stranded d(GA)n and d(GT)n sequence repeats in DNA. Nucleic Acids Res. 21:1993;5221-5228.
9. Bock L.C., Griffin L.C., Latham J.A., Vermaas E.H., Toole J.J. Selection of single-stranded DNA molecules that bind and inhibit human trombin. Nature. 355:1992;564-566.
10. Duncan R., Bazar L., Michelotti G., Tomonaga T., Krutzsch H., Avigan M., Levens D. A sequence-specific single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 8:1994;465-480.
11. Stepleski A., Haas S., Amini S., Khalili K. Regulation of mouse myelin basic protein gene transcription by a sequence-specific single-stranded DNA-binding protein in vitro. Gene. 54:1995;215-218.
12. Ito K., Sato K., Endo H. Cloning and characterization of a single-stranded DNA binding protein that specifically recognizes deoxycytidine stretch. Nucleic Acids Res. 22:1994;53-58.
13. Scaggiante B., Morassutti C., Dapas B., Ustulin F., Tolazzi G., Quadrifoglio F. Human cancer cell lines growth inhibition by GTn oligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins. Eur. J. Biochem. 252:1998;207-215.
14. Crooke M.R. In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anticancer Drug Des. 6:1991;609-646.
15. DeMesmaeker A., Altmann K.H., Waldner A., Wenderborn S. Backbone modifications in oligonucleotides and peptide nucleic acid system. Curr. Opin. Struct. Biol. 5:1995;343-355.
16. Brown D.A., Kang S.H., Gryaznov S.M., Dedionisio L., Heidenreich O., Sullivan S., Xu X., Nerenberg M.I. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269:1994;26801-26805.
17. Guvakova M.A., Yakubov L.A., Vlodavsky I., Tonkinson J.L., Stein C.A. Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270:1995;2620-2627.
18. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., Boyd M. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl. Cancer Inst. 83:1991;757-766.
19. Laemmli E.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;248-252.
20. Dignam J.D., Lebowitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res. 11:1983;1475-1489.
21. Bradford M.M. A rapid sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-252.
22. Morassutti C., Dapas B., Scaggiante B., Paroni G., Xodo L., Quadrifoglio F. Effect of oligomer length and base substitutions on the cytotoxic activity and specific nuclear protein recognition of GTn oligonucleotides in the human leukemic CCRF-CEM cell line. Nucleosides Nucleotides. 18:1999;1711-1716.
23. Dagle J.M., Weeks D.L., Walder J.A. Pathways of degradation and mechanism of action of antisense oligonucleotides in Xenopus laevis embryos. Antisense Res. Dev. 1:1991;11-20.
24. Tonkinson J.L., Stein C.A. Patterns of intracellular compartmentalization, trafficking and acidification of 5'-fluorescein labeled phosphodiester and phosphorothioate oligodeoxynucleotides in HL60 cells. Nucleic Acids Res. 22:1994;4268-4275.
25. Spiller D.G., Tidd D.M. The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells. Anticancer Drug Des. 7:1992;115-129.
26. Marcusson E.G., Balkrishen B., Manoharan M., Bennett C.F., Dean N.M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26:1998;2016-2023.
27. Weidner D.A., Valdez B.C., Henning D., Greenberg S., Busch H. Phosphorothioate oligonucleotides bind in a non sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett. 366:1995;146-150.
28. Ghosh M.K., Ghosh K., Cohen J.S. Translation inhibition by phosphorothioate oligodeoxynucleotides in cell-free systems. Antisense Res. Dev. 2:1992;111-118.
29. Stein C.A. Phosphorothioate antisense oligodeoxynucleotides: questions of specificity. TIBTECH. 14:1996;147-149.
30. Frey P.A., Sammons R.D. Bond order and charge localization in nucleoside phosphorothioates. Science. 228:1985;541-545.
31. Benimetskaya L., Tonkinson J.L., Koziolkiewcz M., Karwowski B., Guga P., Zeltser R., Stec W., Stein C.A. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res. 23:1995;4239-4245.